Drug Trial Radar · NCT04711486
Evaluation of Safety of Contraloid Acetate in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: Aug 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Dec 8, 2020
Primary completion
Jan 13, 2022
Study completion Jan 13, 2022
Sponsor
- Lead sponsor
- Charite University, Berlin, GermanyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Berlin Institute of Health; Federal Agency for Disruptive Innovation - SPRIN-D
- First posted
- Jan 15, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients with mild cognitive impairment due to Alzheimer's disease (MCI due to AD) are at high risk to develop Alzheimer´s dementia. The therapeutic agent Contraloid has the potential to influence the chronic neurodegenerative process of AD. As Contraloid was so far only administered to healthy subjects, the rational of the proposed study is first to collect safety data in patients diagnosed with MCI due to AD, as the absorption, distribution, metabolism and excretion processes may be altered by disease, aging, comorbidities and concomitant drug therapies. Additionally, the design of a subsequent phase II study will be based on the data of this study. The results of the exploratory analyses will enable power calculations and the identification of the most useful and reliable biomarkers for the subsequent proof of concept phase II study.
Conditions
- Mild Cognitive Impairment Due to Alzheimer's Disease
Interventions
Contraloid acetateDrug
Oral administration of drug substance capsules
PlaceboDrug
Oral administration of placebo without any exipients.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety: Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0Time frame: From baseline (day 1) to follow-up (day 56)
- Safety: Number of Participants with abnormal laboratory values (urinalysis, CBC, Quick, PTT, Creatinine, CK, CRP, ALT, AST)Time frame: From baseline (day 1) to follow-up (day 56)
- Safety: Number of Participants with abnormal ECG valuesTime frame: From baseline (day 1) to follow-up (day 56)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Charité University Medicine
Berlin, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.